Related references
Note: Only part of the references are listed.Targeted Modifications in Adeno-Associated Virus Serotype 8 Capsid Improves Its Hepatic Gene Transfer Efficiency In Vivo
Dwaipayan Sen et al.
HUMAN GENE THERAPY METHODS (2013)
Bioengineering of AAV2 Capsid at Specific Serine, Threonine, or Lysine Residues Improves Its Transduction Efficiency in Vitro and in Vivo
Nishanth Gabriel et al.
HUMAN GENE THERAPY METHODS (2013)
The gene therapy journey for hemophilia: are we there yet?
Katherine A. High
BLOOD (2012)
Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer
George Buchlis et al.
BLOOD (2012)
Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia
C. Li et al.
GENE THERAPY (2012)
AAV-based neonatal gene therapy for hemophilia A: long-term correction and avoidance of immune responses in mice
C. Hu et al.
GENE THERAPY (2012)
Directed evolution of novel adeno-associated viruses for therapeutic gene delivery
M. A. Bartel et al.
GENE THERAPY (2012)
AAV2 Gene Therapy Readministration in Three Adults with Congenital Blindness
Jean Bennett et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Universal Real-Time PCR for the Detection and Quantification of Adeno-Associated Virus Serotype 2-Derived Inverted Terminal Repeat Sequences
Christine Aurnhammer et al.
HUMAN GENE THERAPY METHODS (2012)
Adenovirus-Associated Virus Vector-Mediated Gene Transfer in Hemophilia B
Amit C. Nathwani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Sites in the AAV5 capsid tolerant to deletions and tandem duplications
Kaoru Hida et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2010)
Comparative Cardiac Gene Delivery of Adeno-Associated Virus Serotypes 1-9 reveals that AAV6 Mediates the Most Efficient Transduction in Mouse Heart
Carmela Zincarelli et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2010)
Comparison of Adeno-Associated Virus Pseudotype 1, 2, and 8 Vectors Administered by Intramuscular Injection in the Treatment of Murine Phenylketonuria
Alexandre Rebuffat et al.
HUMAN GENE THERAPY (2010)
Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors
Sylvie Boutin et al.
HUMAN GENE THERAPY (2010)
Comparative Transduction Efficiency of AAV Vector Serotypes 1-6 in the Substantia Nigra and Striatum of the Primate Brain
Eleni A. Markakis et al.
MOLECULAR THERAPY (2010)
Proteasome Inhibitors Decrease AAV2 Capsid-derived Peptide Epitope Presentation on MHC Class I Following Transduction
Jonathan D. Finn et al.
MOLECULAR THERAPY (2010)
Effect of Adeno-Associated Virus Serotype and Genomic Structure on Liver Transduction and Biodistribution in Mice of Both Genders
Astrid Paneda et al.
HUMAN GENE THERAPY (2009)
Adeno-associated virus serotype 2 induces cell-mediated immune responses directed against multiple epitopes of the capsid protein VP1
Declan Madsen et al.
JOURNAL OF GENERAL VIROLOGY (2009)
Worldwide Epidemiology of Neutralizing Antibodies to Adeno-Associated Viruses
Roberto Calcedo et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
Gene Therapy Using Adeno-Associated Virus Vectors
Shyam Daya et al.
CLINICAL MICROBIOLOGY REVIEWS (2008)
Transient immunomodulation allows repeated injections of AAV1 and correction of muscular dystrophy in multiple muscles
Stephanie Lorain et al.
MOLECULAR THERAPY (2008)
Prolonged susceptibility to antibody-mediated neutralization for adeno-associated vectors targeted to the liver
Samuel L. Murphy et al.
MOLECULAR THERAPY (2008)
Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection
Carmela Zincarelli et al.
MOLECULAR THERAPY (2008)
Next generation of adeno-associated virus 2 vectors: Point mutations in tyrosines lead to high-efficiency transduction at lower doses
Li Zhong et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver
Federico Mingozzi et al.
BLOOD (2007)
CD8+ T-cell responses to adeno-associated virus capsid in humans
Federico Mingozzi et al.
NATURE MEDICINE (2007)
Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates
Amit C. Nathwani et al.
BLOOD (2007)
Viral vector-mediated and cell-based therapies for treatment of cystic fibrosis
Terence R. Flotte et al.
MOLECULAR THERAPY (2007)
Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes
Zhijian Wu et al.
JOURNAL OF VIROLOGY (2006)
Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors
CL Halbert et al.
HUMAN GENE THERAPY (2006)
Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response
CS Manno et al.
NATURE MEDICINE (2006)
Directed evolution of adeno-associated virus yields enhanced gene delivery vectors
N Maheshri et al.
NATURE BIOTECHNOLOGY (2006)
Adeno-associated virus serotypes: Vector toolkit for human gene therapy
Zhijian Wu et al.
MOLECULAR THERAPY (2006)
New recombinant serotypes of AAV vectors
GP Gao et al.
CURRENT GENE THERAPY (2005)
Hybrid vectors based on adeno-associated virus serotypes 2 and 5 for muscle-directed gene transfer
M Hildinger et al.
JOURNAL OF VIROLOGY (2001)
Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer
J Zabner et al.
JOURNAL OF VIROLOGY (2000)
Share Paper
